Stay updated on Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial page.

Latest updates to the Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version v2.16.1 to v2.16.2.SummaryDifference0.1%
- Check17 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check24 days agoNo Change Detected
- Check45 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check60 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed descriptions of a phase II study on VRP-HER2 immunizations and pembrolizumab for breast cancer, while adding a new version revision and a mention of the study's location.SummaryDifference44%
- Check67 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for March 12, 2025. However, the deletion of the date March 25, 2025, indicates a potential change in scheduling or availability.SummaryDifference0.2%
- Check89 days agoChange DetectedThe webpage has updated its date references, replacing older dates from 2024 with new dates in 2025, indicating a shift in the timeline for content or events.SummaryDifference0.7%
Stay in the know with updates to Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial page.